N 566 / MN566 FINAL
M
EXAM 2026-2027 | Latest
Update | 100% Correct
Verified Q&A | Grade A | Pass
Guaranteed
=======================================================================
=
========
PART A – MULTIPLE CHOICE (Q1–100)
========================================================================
========
CARDIOVASCULAR (20%) – Questions 1-24
Q1 (Cardiovascular – Hypertension): A 58-year-old African American man presents with BP
158/96 mmHg on two separate occasions. He has no diabetes or CKD. According to ACC/AHA
2026 guidelines, what is the most appropriate first-line pharmacotherapy?
A. ACE inhibitor
B. Thiazide-like diuretic or calcium channel blocker
C. Beta-blocker
D. ARB
[CORRECT] B
Rationale: ACC/AHA 2026 guidelines recommend thiazide-like diuretics or calcium channel
blockers as first-line for non-diabetic African American patients due to superior BP reduction
and cardiovascular outcomes in this population; ACE inhibitors/ARBs are less effective as
monotherapy in African Americans without compelling indications. Beta-blockers are not
first-line for uncomplicated hypertension. Clinical pearl: If this patient had HF or CKD, ACEi/ARB
would be indicated regardless of race.
Q2 (Cardiovascular – Hypertension): A 45-year-old woman with hypertension (BP 142/88
mmHg) and stage 3 CKD (eGFR 45 mL/min/1.73m², UACR 45 mg/g) is started on lisinopril 10
mg daily. What is the target BP goal per 2026 KDIGO/ACC/AHA consensus?
A. <140/90 mmHg
B. <130/80 mmHg
C. <150/90 mmHg if ≥65 years
, . <120/80 mmHg
D
[CORRECT] B
Rationale: For patients with CKD and albuminuria (UACR ≥30 mg/g), the 2026
KDIGO/ACC/AHA consensus recommends a target BP <130/80 mmHg to slow CKD
progression and reduce cardiovascular events; ACEi/ARB is first-line for albuminuric CKD.
Option A is for standard-risk patients without compelling indications. Clinical pearl: Monitor
potassium and creatinine 1-2 weeks after starting ACEi/ARB in CKD patients.
Q3 (Cardiovascular – Heart Failure): A 72-year-old man with HFrEF (LVEF 30%) is on lisinopril
20 mg, carvedilol 25 mg BID, and furosemide 40 mg daily. He remains symptomatic (NYHA
Class III). Which GDMT addition is most appropriate per 2026 ACC/AHA/HFSA guidelines?
A. Digoxin 0.125 mg daily
B. Sacubitril/valsartan (ARNI) replacing lisinopril
C. Hydralazine/isosorbide dinitrate
D. Ivabradine
[CORRECT] B
Rationale: 2026 ACC/AHA/HFSA guidelines recommend replacing ACEi/ARB with ARNI
(sacubitril/valsartan) in symptomatic HFrEF (NYHA II-III) to reduce mortality and hospitalization;
PARADIGM-HF trial showed 20% reduction in cardiovascular death vs. enalapril.
Hydralazine/isosorbide is for African Americans or ACEi/ARB-intolerant patients. Clinical pearl:
Allow 36-hour washout between ACEi and ARNI to avoid angioedema.
Q4 (Cardiovascular – Heart Failure): A 68-year-old woman with HFpEF (LVEF 55%, elevated
BNP, NYHA Class II-III) has persistent dyspnea despite optimal diuretic therapy. Which
medication has demonstrated mortality benefit in HFpEF per 2026 guidelines?
A. Spironolactone
B. SGLT2 inhibitor (dapagliflozin or empagliflozin)
C. Sacubitril/valsartan
D. Verapamil
[CORRECT] B
Rationale: The EMPEROR-Preserved and DELIVER trials (2026 updates) demonstrated that
SGLT2 inhibitors reduce cardiovascular death and heart failure hospitalization in HFpEF
regardless of diabetes status; 2026 ACC/AHA/HFSA guidelines now recommend SGLT2i as
foundational therapy for HFpEF. Spironolactone showed benefit only in TOPCAT post-hoc
analysis. Clinical pearl: SGLT2i is now the only GDMT with proven mortality/morbidity benefit in
HFpEF.
Q5 (Cardiovascular – Dyslipidemia): A 62-year-old man with ASCVD (prior MI 2 years ago) has
LDL 82 mg/dL on atorvastatin 40 mg. According to 2026 ACC/AHA cholesterol guidelines, what
is the next step?
A. Continue current therapy; LDL goal achieved
B. Add ezetimibe 10 mg daily
C. Switch to rosuvastatin 40 mg
D. Add PCSK9 inhibitor
[CORRECT] B
Rationale: 2026 ACC/AHA guidelines recommend LDL <70 mg/dL for secondary prevention in
very high-risk ASCVD patients; if LDL remains ≥70 mg/dL on maximally tolerated statin, add
, zetimibe (IMPROVE-IT trial showed additional benefit). PCSK9 inhibitors are reserved if LDL
e
≥70 mg/dL on statin + ezetimibe. Clinical pearl: "Lower is better" for secondary prevention—aim
for LDL <70, <55, or <40 depending on risk stratification.
Q6 (Cardiovascular – Dyslipidemia): A 55-year-old woman with heterozygous familial
hypercholesterolemia (LDL 210 mg/dL) is intolerant to statins (myalgia). Which is the first-line
non-statin therapy per 2026 guidelines?
A. Ezetimibe 10 mg daily
B. Bempedoic acid 180 mg daily
C. Evolocumab 140 mg every 2 weeks
D. Inclisiran 284 mg every 6 months
[CORRECT] B
Rationale: 2026 ACC/AHA guidelines recommend bempedoic acid as first-line non-statin
therapy for statin-intolerant patients with FH; CLEAR trial showed 17-18% LDL reduction and
reduced MACE. Ezetimibe alone is insufficient for FH (LDL typically >190). PCSK9 inhibitors are
second-line if LDL remains elevated on bempedoic acid ± ezetimibe. Clinical pearl: Bempedoic
acid is a prodrug activated in liver (not muscle), explaining reduced myalgia risk.
Q7 (Cardiovascular – CAD): A 67-year-old man with stable CAD presents with exertional chest
pain. He is on aspirin 81 mg, atorvastatin 40 mg, and metoprolol 50 mg BID. What is the optimal
antianginal to add per 2026 AHA/ACC stable ischemic heart disease guidelines?
A. Ranolazine 500 mg BID
B. Amlodipine 5 mg daily
C. Isosorbide mononitrate 30 mg daily
D. Nicorandil
[CORRECT] B
Rationale: 2026 AHA/ACC guidelines recommend calcium channel blockers (amlodipine) or
long-acting nitrates as second-line antianginals after beta-blockers; amlodipine is preferred in
patients with preserved LV function and hypertension. Ranolazine is third-line or for refractory
angina. Clinical pearl: Avoid short-acting nitrates within 24 hours of PDE5 inhibitors (sildenafil,
tadalafil) due to profound hypotension risk.
Q8 (Cardiovascular – CAD): A 71-year-old woman with NSTEMI is managed medically. She has
no contraindications to anticoagulation. According to 2026 ACC/AHA guidelines, what is the
recommended duration of dual antiplatelet therapy (DAPT) with aspirin + clopidogrel?
A. 1 month
B. 3 months
C. 6-12 months
D. Indefinite
[CORRECT] C
Rationale: 2026 ACC/AHA guidelines recommend DAPT for 6-12 months after ACS
(NSTEMI/STEMI) managed medically or with PCI; shorter duration (3 months) may be
considered for high bleeding risk, longer (12+ months) for high ischemic risk. Aspirin is
continued indefinitely. Clinical pearl: Use P2Y12 inhibitor (clopidogrel/prasugrel/ticagrelor)
without aspirin for patients requiring oral anticoagulation (AFib) to reduce bleeding
(WOEST/AFIRE strategy).
, 9 (Cardiovascular – Hypertension): A 52-year-old man with resistant hypertension (BP 156/94
Q
mmHg on lisinopril 40 mg, amlodipine 10 mg, and chlorthalidone 25 mg) has potassium 4.2
mEq/L and creatinine 1.1 mg/dL. What is the next best step?
A. Increase chlorthalidone to 50 mg
B. Add spironolactone 25 mg daily
C. Switch to hydralazine/isosorbide
D. Add clonidine 0.1 mg BID
[CORRECT] B
Rationale: PATHWAY-2 trial and 2026 ACC/AHA guidelines recommend spironolactone as
fourth-line therapy for resistant hypertension; it is the most effective add-on agent, reducing SBP
by ~8-15 mmHg. Monitor potassium closely (risk of hyperkalemia, especially if eGFR <45).
Clinical pearl: True resistant hypertension requires confirmation with ambulatory BP monitoring
to exclude white-coat effect or non-adherence.
Q10 (Cardiovascular – Heart Failure): A 74-year-old man with HFrEF is started on dapagliflozin
10 mg daily. Which monitoring parameter is most critical in the first 2 weeks?
A. Liver function tests
B. Serum creatinine and eGFR
C. Hemoglobin A1c
D. Brain natriuretic peptide (BNP)
[CORRECT] B
Rationale: SGLT2 inhibitors cause initial eGFR decline (10-15%) due to tubuloglomerular
feedback; 2026 guidelines recommend checking creatinine/eGFR at 2-4 weeks after
initiation—if eGFR declines >30% or to <25 mL/min/1.73m², hold and reassess. This is usually
reversible and hemodynamically mediated. Clinical pearl: SGLT2i can be continued down to
eGFR 20 mL/min/1.73m² for HF; do not stop for modest initial creatinine rise.
Q11 (Cardiovascular – CAD): A 63-year-old man with STEMI undergoes primary PCI. He has no
history of bleeding. What is the preferred P2Y12 inhibitor per 2026 ACC/AHA guidelines?
A. Clopidogrel 75 mg daily
B. Prasugrel 10 mg daily
C. Ticagrelor 90 mg BID
D. Cangrelor IV
[CORRECT] B
Rationale: 2026 ACC/AHA STEMI guidelines prefer prasugrel over clopidogrel for primary PCI
in patients without prior stroke/TIA (TRITON-TIMI 38 showed reduced stent thrombosis and CV
death); ticagrelor is acceptable alternative. Prasugrel is contraindicated if prior stroke/TIA or age
>75/weight <60 kg (use 5 mg dose if 60+ years and <60 kg). Clinical pearl: Prasugrel must be
given after coronary anatomy is known (not upstream in undifferentiated chest pain).
Q12 (Cardiovascular – Dyslipidemia): A 48-year-old woman with diabetes (A1C 7.2%) and no
ASCVD has LDL 118 mg/dL. What is the appropriate statin intensity per 2026 ADA/ACC
guidelines?
A. No statin needed; LDL <130
B. Low-intensity statin
C. Moderate-intensity statin
D. High-intensity statin
M
EXAM 2026-2027 | Latest
Update | 100% Correct
Verified Q&A | Grade A | Pass
Guaranteed
=======================================================================
=
========
PART A – MULTIPLE CHOICE (Q1–100)
========================================================================
========
CARDIOVASCULAR (20%) – Questions 1-24
Q1 (Cardiovascular – Hypertension): A 58-year-old African American man presents with BP
158/96 mmHg on two separate occasions. He has no diabetes or CKD. According to ACC/AHA
2026 guidelines, what is the most appropriate first-line pharmacotherapy?
A. ACE inhibitor
B. Thiazide-like diuretic or calcium channel blocker
C. Beta-blocker
D. ARB
[CORRECT] B
Rationale: ACC/AHA 2026 guidelines recommend thiazide-like diuretics or calcium channel
blockers as first-line for non-diabetic African American patients due to superior BP reduction
and cardiovascular outcomes in this population; ACE inhibitors/ARBs are less effective as
monotherapy in African Americans without compelling indications. Beta-blockers are not
first-line for uncomplicated hypertension. Clinical pearl: If this patient had HF or CKD, ACEi/ARB
would be indicated regardless of race.
Q2 (Cardiovascular – Hypertension): A 45-year-old woman with hypertension (BP 142/88
mmHg) and stage 3 CKD (eGFR 45 mL/min/1.73m², UACR 45 mg/g) is started on lisinopril 10
mg daily. What is the target BP goal per 2026 KDIGO/ACC/AHA consensus?
A. <140/90 mmHg
B. <130/80 mmHg
C. <150/90 mmHg if ≥65 years
, . <120/80 mmHg
D
[CORRECT] B
Rationale: For patients with CKD and albuminuria (UACR ≥30 mg/g), the 2026
KDIGO/ACC/AHA consensus recommends a target BP <130/80 mmHg to slow CKD
progression and reduce cardiovascular events; ACEi/ARB is first-line for albuminuric CKD.
Option A is for standard-risk patients without compelling indications. Clinical pearl: Monitor
potassium and creatinine 1-2 weeks after starting ACEi/ARB in CKD patients.
Q3 (Cardiovascular – Heart Failure): A 72-year-old man with HFrEF (LVEF 30%) is on lisinopril
20 mg, carvedilol 25 mg BID, and furosemide 40 mg daily. He remains symptomatic (NYHA
Class III). Which GDMT addition is most appropriate per 2026 ACC/AHA/HFSA guidelines?
A. Digoxin 0.125 mg daily
B. Sacubitril/valsartan (ARNI) replacing lisinopril
C. Hydralazine/isosorbide dinitrate
D. Ivabradine
[CORRECT] B
Rationale: 2026 ACC/AHA/HFSA guidelines recommend replacing ACEi/ARB with ARNI
(sacubitril/valsartan) in symptomatic HFrEF (NYHA II-III) to reduce mortality and hospitalization;
PARADIGM-HF trial showed 20% reduction in cardiovascular death vs. enalapril.
Hydralazine/isosorbide is for African Americans or ACEi/ARB-intolerant patients. Clinical pearl:
Allow 36-hour washout between ACEi and ARNI to avoid angioedema.
Q4 (Cardiovascular – Heart Failure): A 68-year-old woman with HFpEF (LVEF 55%, elevated
BNP, NYHA Class II-III) has persistent dyspnea despite optimal diuretic therapy. Which
medication has demonstrated mortality benefit in HFpEF per 2026 guidelines?
A. Spironolactone
B. SGLT2 inhibitor (dapagliflozin or empagliflozin)
C. Sacubitril/valsartan
D. Verapamil
[CORRECT] B
Rationale: The EMPEROR-Preserved and DELIVER trials (2026 updates) demonstrated that
SGLT2 inhibitors reduce cardiovascular death and heart failure hospitalization in HFpEF
regardless of diabetes status; 2026 ACC/AHA/HFSA guidelines now recommend SGLT2i as
foundational therapy for HFpEF. Spironolactone showed benefit only in TOPCAT post-hoc
analysis. Clinical pearl: SGLT2i is now the only GDMT with proven mortality/morbidity benefit in
HFpEF.
Q5 (Cardiovascular – Dyslipidemia): A 62-year-old man with ASCVD (prior MI 2 years ago) has
LDL 82 mg/dL on atorvastatin 40 mg. According to 2026 ACC/AHA cholesterol guidelines, what
is the next step?
A. Continue current therapy; LDL goal achieved
B. Add ezetimibe 10 mg daily
C. Switch to rosuvastatin 40 mg
D. Add PCSK9 inhibitor
[CORRECT] B
Rationale: 2026 ACC/AHA guidelines recommend LDL <70 mg/dL for secondary prevention in
very high-risk ASCVD patients; if LDL remains ≥70 mg/dL on maximally tolerated statin, add
, zetimibe (IMPROVE-IT trial showed additional benefit). PCSK9 inhibitors are reserved if LDL
e
≥70 mg/dL on statin + ezetimibe. Clinical pearl: "Lower is better" for secondary prevention—aim
for LDL <70, <55, or <40 depending on risk stratification.
Q6 (Cardiovascular – Dyslipidemia): A 55-year-old woman with heterozygous familial
hypercholesterolemia (LDL 210 mg/dL) is intolerant to statins (myalgia). Which is the first-line
non-statin therapy per 2026 guidelines?
A. Ezetimibe 10 mg daily
B. Bempedoic acid 180 mg daily
C. Evolocumab 140 mg every 2 weeks
D. Inclisiran 284 mg every 6 months
[CORRECT] B
Rationale: 2026 ACC/AHA guidelines recommend bempedoic acid as first-line non-statin
therapy for statin-intolerant patients with FH; CLEAR trial showed 17-18% LDL reduction and
reduced MACE. Ezetimibe alone is insufficient for FH (LDL typically >190). PCSK9 inhibitors are
second-line if LDL remains elevated on bempedoic acid ± ezetimibe. Clinical pearl: Bempedoic
acid is a prodrug activated in liver (not muscle), explaining reduced myalgia risk.
Q7 (Cardiovascular – CAD): A 67-year-old man with stable CAD presents with exertional chest
pain. He is on aspirin 81 mg, atorvastatin 40 mg, and metoprolol 50 mg BID. What is the optimal
antianginal to add per 2026 AHA/ACC stable ischemic heart disease guidelines?
A. Ranolazine 500 mg BID
B. Amlodipine 5 mg daily
C. Isosorbide mononitrate 30 mg daily
D. Nicorandil
[CORRECT] B
Rationale: 2026 AHA/ACC guidelines recommend calcium channel blockers (amlodipine) or
long-acting nitrates as second-line antianginals after beta-blockers; amlodipine is preferred in
patients with preserved LV function and hypertension. Ranolazine is third-line or for refractory
angina. Clinical pearl: Avoid short-acting nitrates within 24 hours of PDE5 inhibitors (sildenafil,
tadalafil) due to profound hypotension risk.
Q8 (Cardiovascular – CAD): A 71-year-old woman with NSTEMI is managed medically. She has
no contraindications to anticoagulation. According to 2026 ACC/AHA guidelines, what is the
recommended duration of dual antiplatelet therapy (DAPT) with aspirin + clopidogrel?
A. 1 month
B. 3 months
C. 6-12 months
D. Indefinite
[CORRECT] C
Rationale: 2026 ACC/AHA guidelines recommend DAPT for 6-12 months after ACS
(NSTEMI/STEMI) managed medically or with PCI; shorter duration (3 months) may be
considered for high bleeding risk, longer (12+ months) for high ischemic risk. Aspirin is
continued indefinitely. Clinical pearl: Use P2Y12 inhibitor (clopidogrel/prasugrel/ticagrelor)
without aspirin for patients requiring oral anticoagulation (AFib) to reduce bleeding
(WOEST/AFIRE strategy).
, 9 (Cardiovascular – Hypertension): A 52-year-old man with resistant hypertension (BP 156/94
Q
mmHg on lisinopril 40 mg, amlodipine 10 mg, and chlorthalidone 25 mg) has potassium 4.2
mEq/L and creatinine 1.1 mg/dL. What is the next best step?
A. Increase chlorthalidone to 50 mg
B. Add spironolactone 25 mg daily
C. Switch to hydralazine/isosorbide
D. Add clonidine 0.1 mg BID
[CORRECT] B
Rationale: PATHWAY-2 trial and 2026 ACC/AHA guidelines recommend spironolactone as
fourth-line therapy for resistant hypertension; it is the most effective add-on agent, reducing SBP
by ~8-15 mmHg. Monitor potassium closely (risk of hyperkalemia, especially if eGFR <45).
Clinical pearl: True resistant hypertension requires confirmation with ambulatory BP monitoring
to exclude white-coat effect or non-adherence.
Q10 (Cardiovascular – Heart Failure): A 74-year-old man with HFrEF is started on dapagliflozin
10 mg daily. Which monitoring parameter is most critical in the first 2 weeks?
A. Liver function tests
B. Serum creatinine and eGFR
C. Hemoglobin A1c
D. Brain natriuretic peptide (BNP)
[CORRECT] B
Rationale: SGLT2 inhibitors cause initial eGFR decline (10-15%) due to tubuloglomerular
feedback; 2026 guidelines recommend checking creatinine/eGFR at 2-4 weeks after
initiation—if eGFR declines >30% or to <25 mL/min/1.73m², hold and reassess. This is usually
reversible and hemodynamically mediated. Clinical pearl: SGLT2i can be continued down to
eGFR 20 mL/min/1.73m² for HF; do not stop for modest initial creatinine rise.
Q11 (Cardiovascular – CAD): A 63-year-old man with STEMI undergoes primary PCI. He has no
history of bleeding. What is the preferred P2Y12 inhibitor per 2026 ACC/AHA guidelines?
A. Clopidogrel 75 mg daily
B. Prasugrel 10 mg daily
C. Ticagrelor 90 mg BID
D. Cangrelor IV
[CORRECT] B
Rationale: 2026 ACC/AHA STEMI guidelines prefer prasugrel over clopidogrel for primary PCI
in patients without prior stroke/TIA (TRITON-TIMI 38 showed reduced stent thrombosis and CV
death); ticagrelor is acceptable alternative. Prasugrel is contraindicated if prior stroke/TIA or age
>75/weight <60 kg (use 5 mg dose if 60+ years and <60 kg). Clinical pearl: Prasugrel must be
given after coronary anatomy is known (not upstream in undifferentiated chest pain).
Q12 (Cardiovascular – Dyslipidemia): A 48-year-old woman with diabetes (A1C 7.2%) and no
ASCVD has LDL 118 mg/dL. What is the appropriate statin intensity per 2026 ADA/ACC
guidelines?
A. No statin needed; LDL <130
B. Low-intensity statin
C. Moderate-intensity statin
D. High-intensity statin
